Autonomix Medical Business Summary

Autonomix Medical, Inc. (AMIX) is a development-stage medical device company focused on commercializing a proprietary technology platform for the sensing and treatment of peripheral nervous system disorders. The company’s business model is centered on the development of its first-in-class, catheter-based microchip sensing array, which is designed to detect and differentiate neural signals with up to 1,000 times the sensitivity of existing technologies. Revenue is projected to be generated through the sale of its specialized catheters and integrated sensing/ablation hardware, targeting high-value clinical segments such as chronic pain management, cardiology, and oncology. Currently, the company is prioritizing its clinical program for pancreatic cancer pain, utilizing a transvascular approach to ablate malfunctioning nerves. In the competitive landscape, Autonomix operates alongside medical technology firms such as PAVmed (PAVM), Catheter Precision (VTAK), and Sintx Technologies (SINT), positioning itself as a high-sensitivity specialist in the niche of neural signal detection and precision denervation. The leadership team is anchored by a group of seasoned MedTech executives with a significant track record of successful exits. President and CEO Brad Hauser previously served as CEO of Soliton, Inc., where he led the company through its $550 million acquisition by AbbVie. He is supported by Executive Chairman Walter Klemp and Executive Vice Chairman Lori Bisson, both of whom held top leadership roles at Soliton and Moleculin Biotech. The company’s technical foundation rests on co-founders Dr. Robert Schwartz, the Chief Medical Officer and inventor of the billion-dollar Watchman cardiology device (acquired by Boston Scientific), and Chief Technology Officer Landy Toth, an expert in microchip-enabled medical sensors. Notable institutional backing includes Heights Capital Management, reflecting strong investor interest in the company’s intellectual property portfolio and its potential to disrupt the multi-billion-dollar market for neurological pain interventions.